MYX 3.25% $4.77 mayne pharma group limited

"We'd hope MYX with Nextstellis is different - we are just...

  1. 200 Posts.
    lightbulb Created with Sketch. 119
    "We'd hope MYX with Nextstellis is different - we are just talking about "cycles". Regardless of which way they are reported - the growth rates are similar and unfortunately the last few months have been flat. Reporting type is semantics as the market is wanting revenue growth for a product that has cost Hundreds and Hundreds and Hundreds of $millions."

    The definition of semantics is "meaning the same thing", clearly IQVIA cycles (as presented in May) are 23% lower on average than demand cycles (as presented in Feb), so not the same thing and not semantics. I am sure Mithra would not have been happy to be paid licence fees based on IQVIA cycles which are 23% lower. So cycles ain't cycles.
    As far as cycles growth rates, this year's growth average is 4.6%, not great but not flat and I agree that the market wants to see revenue growth but no figures have been made available but I am sure that if demand cycles had been presented instead of IQVIA cycles, the market might be factoring in revenue growth of a different kind.

 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
(20min delay)
Last
$4.77
Change
-0.160(3.25%)
Mkt cap ! $405.8M
Open High Low Value Volume
$4.94 $5.02 $4.75 $1.848M 380.8K

Buyers (Bids)

No. Vol. Price($)
2 4114 $4.77
 

Sellers (Offers)

Price($) Vol. No.
$4.80 109 1
View Market Depth
Last trade - 16.10pm 06/06/2024 (20 minute delay) ?
Last
$4.79
  Change
-0.160 ( 2.42 %)
Open High Low Volume
$4.98 $5.02 $4.75 100660
Last updated 15.59pm 06/06/2024 ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.